Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Disis

Showing results (111-120 of 189) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Clinical studies of vaccines targeting breast cancerByung K Ko, Kouichiro Kawano, James L Murray, et al.
Breast Cancer Research and Treatment|February 1, 2008
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunityAndrew L Coveler, Vivian Goodell, Devon J Webster, et al.
Journal of Immune Based Therapies and Vaccines|May 5, 2007
Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donorsSmita A Ghanekar, Sonny Bhatia, Joyce J Ruitenberg, et al.
Cancer Research|October 17, 2008
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancerKyong Hwa Park, Ekram Gad, Vivian Goodell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune ResponsesDenise L Cecil, John B Liao, Yushe Dang, et al.
Molecular Cancer Therapeutics|March 14, 2020
Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary CancersMary L Disis, Lauren R Corulli, Ekram A Gad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2010
Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cellsHailing Lu, Yi Yang, Ekram Gad, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 20, 2006
Immunoediting of cancers may lead to epithelial to mesenchymal transitionKeith L Knutson, Hailing Lu, Brad Stone, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 21, 2012
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer seraHailing Lu, Jon Ladd, Ziding Feng, et al.
Scientific Reports|August 10, 2022
Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancerDenise L Cecil, Benjamin Curtis, Ekram Gad, et al.
Pageof 19

Showing results (111-120 of 189) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Clinical studies of vaccines targeting breast cancerByung K Ko, Kouichiro Kawano, James L Murray, et al.
Breast Cancer Research and Treatment|February 1, 2008
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunityAndrew L Coveler, Vivian Goodell, Devon J Webster, et al.
Journal of Immune Based Therapies and Vaccines|May 5, 2007
Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donorsSmita A Ghanekar, Sonny Bhatia, Joyce J Ruitenberg, et al.
Cancer Research|October 17, 2008
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancerKyong Hwa Park, Ekram Gad, Vivian Goodell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune ResponsesDenise L Cecil, John B Liao, Yushe Dang, et al.
Molecular Cancer Therapeutics|March 14, 2020
Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary CancersMary L Disis, Lauren R Corulli, Ekram A Gad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2010
Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cellsHailing Lu, Yi Yang, Ekram Gad, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 20, 2006
Immunoediting of cancers may lead to epithelial to mesenchymal transitionKeith L Knutson, Hailing Lu, Brad Stone, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 21, 2012
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer seraHailing Lu, Jon Ladd, Ziding Feng, et al.
Scientific Reports|August 10, 2022
Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancerDenise L Cecil, Benjamin Curtis, Ekram Gad, et al.
Pageof 19